Titan International, Inc.
NYSE:TWIAgricultural - Machinery
+$0.24 today
- Market cap
- $283.62M
- Beta
- 1.47
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$1.36
Volume 0.77M
Average 0.93M
TWI Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Titan International, Inc.NYSE: TWI
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows in line with its trailing trend
Q1 FY2026 depreciation & amortization of $17.07M rose 7.6% year over year, ahead of the +5.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.2% from the prior quarter. Over 3 fiscal years it compounded at +16.2% a year.
Context
- Depreciation & amortization amounted to 3.7% of revenue in FY2025, up 0.4 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +7.6% holds above the trailing-twelve-month pace of +5.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 67.11M USD
- Year-over-year change
- +10.6%
- 4-year CAGR
- +8.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 67.11M | +10.6% |
| FY2024 | 2024-12-31 | 60.7M | +43.1% |
| FY2023 | 2023-12-31 | 42.43M | -0.7% |
| FY2022 | 2022-12-31 | 42.75M | -10.9% |
| FY2021 | 2021-12-31 | 47.99M | — |
Depreciation & Amortization vs competitors
How TWI compares with its peers on the latest reported figures
- TWI's LTM Mar 2026 depreciation & amortization of $68.31M is the 4th largest of the 11 companies compared; the peer median is $50.16M.
- Its year-over-year change of +5.8% is the 5th highest of 10, against a peer median of +3.6%.
- Depreciation & amortization amounts to 3.7% of revenue for TWI, versus a peer median of 7.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $137.56M | -3.2% | +7.3% | 7.4% | |
| LTM Mar 2026 | $94.91M | +8.8% | +17.3% | 7.9% | |
| LTM Mar 2026 | $89.26M | +85.2% | +22.5% | 7.5% | |
| LTM Mar 2026 | $68.31M | +5.8% | +16.2% | 3.7% | |
| LTM Mar 2026 | $62.3M | -1.3% | -0.4% | 2.8% | |
| LTM Dec 2025 | $59.88M | +3.0% | +6.5% | 21.7% | |
| LTM Mar 2026 | $40.44M | +30.8% | +5.0% | 12.5% | |
| LTM Mar 2026 | $29M | +3.6% | +0.0% | 2.7% | |
| LTM Mar 2026 | $26.47M | -14.4% | +6.8% | 14.5% | |
| LTM Mar 2026 | $12.79M | — | +7.8% | 14.5% | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | $9.29M | +53.2% | +12.7% | 3.7% |
| Peer median (excluding TWI) | $50.16M | +3.6% | +7.0% | 7.7% | |
Competitors are the stored peer set for TWI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 49.89M | 179.19M | 83.71M | (3.59M) | (63.49M) |
| Depreciation & Amortization | 47.99M | 42.75M | 42.43M | 60.7M | 67.11M |
| Deferred Income Tax | (14.18M) | (55.43M) | (2.08M) | (6.36M) | 30.99M |
| Stock-Based Compensation | 3.44M | 4.28M | 5.24M | 5.4M | 0 |
| Change in Working Capital | (84.17M) | (25.07M) | 32.29M | 88.47M | (21.76M) |
| Accounts Receivables | (74.74M) | (27.2M) | 42.87M | 73.83M | (3.98M) |
| Inventory | (112.85M) | (19.6M) | 31.64M | 51.48M | (7.12M) |
| Accounts Payables | 121.19M | (7.75M) | (62.73M) | (29.17M) | 11.3M |
| Other Working Capital | (17.78M) | 29.48M | 20.51M | (7.67M) | (21.97M) |
| Other Non-Cash Items | 7.76M | 14.96M | 17.77M | (3.14M) | 17.19M |
| Operating Cash Flow | 10.73M | 160.68M | 179.35M | 141.49M | 30.03M |
| Capital Expenditures | (38.8M) | (46.97M) | (60.8M) | (65.62M) | (54.62M) |
| Acquisitions (Net) | 0 | 9.29M | 0 | (143.64M) | 0 |
| Purchases of Investments | 0 | (9.29M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 9.29M | 2.09M | 1.79M | 0 |
| Other Investing Activities | 1.2M | 930K | 1.79M | 5.88M | (5.03M) |
| Investing Cash Flow | (37.6M) | (36.75M) | (56.92M) | (201.6M) | (59.65M) |
| Debt Repayment | 14.97M | (35.8M) | (20.94M) | 142.91M | 17.44M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (25M) | (32.58M) | (74.02M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.02M) | (511K) | (2.5M) | (4.34M) | 6K |
| Financing Cash Flow | 13.95M | (61.31M) | (56.02M) | 64.55M | 17.45M |
| Effect of Forex Changes | (6.4M) | (1.15M) | (5.74M) | (28.72M) | 19.08M |
| Net Change in Cash | (19.32M) | 61.47M | 60.67M | (24.28M) | 6.91M |
| Free Cash Flow | (28.08M) | 113.7M | 118.55M | 75.86M | (24.59M) |
Titan International, Inc.
NYSE:TWI
Intrinsic Alpha fair value
Locked
Current Price
$4.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.